Amphastar Pharma (AMPH) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018
March 12, 2019 4:05 PM EDTReports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018
RANCHO CUCAMONGA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months and full year ended December 31, 2018.
Fourth Quarter Highlights
Net revenues of $89.7 million for the fourth quarter, up 48% from the quarter ended December 31, 2017GAAP net income attributable to Amphastar of $1.9 million, or $0.04 per diluted share, for the fourth quarterAdjusted non-GAAP net income attributable to Amphastar of $6.2 million, or... More